PRDX1 and colitis: In our study, the application of a monoclonal antibody targeting Prdx1 significantly improved disease outcomes in DSS-induced colitis mice, including restoration of colonic epithelial integrity, preservation of mucosal architecture, decrease in disease activity, and attenuation of colonic inflammation.